The selective neuropeptide Y Y5 agonist [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]hPP differently modulates emotional processes and body weight in the rat

Behavioural Brain Research

Volumn 233, Issue 2, 2012, Pages 298-304

  Morales Medina, J C ^a,b   Dominguez Lopez, S ^a   Gobbi, G ^a   Beck Sickinger, A G ^c   Quirion, R ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Anxiety; Corticosterone; Depression; Neuropeptide Y; Olfactory bulbectomy

Indexed keywords

CORTICOSTERONE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; EMOTION; FORCED SWIMMING TEST; GROOMING; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; REARING; SOCIAL BEHAVIOR; SPRAGUE DAWLEY RAT; WEIGHT CONTROL; WISTAR RAT;

ABLATION TECHNIQUES; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EMOTIONS; EXPLORATORY BEHAVIOR; IMMOBILITY RESPONSE, TONIC; INTERPERSONAL RELATIONS; MALE; MAZE LEARNING; NEUROPEPTIDE Y; OLFACTORY BULB; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; SWIMMING;

EID: 84862279110     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.05.015     Document Type: Article

References (66)

1. Kertz S.J., Woodruff-Borden J. Human and economic burden of GAD, subthreshold GAD, and worry in a Primary care sample. Journal of Clinical Psychology in Medical Settings 2011, 18:281-290.
2. McLean C.P., Asnaani A., Litz B.T., Hofmann S.G. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. Journal of Psychiatric Research 2011, 45:1027-1035.
3. Roy-Byrne P.P., Davidson K.W., Kessler R.C., Asmundson G.J., Goodwin R.D., Kubzansky L., et al. Anxiety disorders and comorbid medical illness. General Hospital Psychiatry 2008, 30:208-225.
4. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABA(A) receptor subtypes. Nature Reviews Drug Discovery 2011, 10:685-697.
5. Morales-Medina J.C., Dumont Y., Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Research 2010, 1314:194-205.
6. Morales-Medina J.C., Quirion R. Role of neuropeptide Y in depression: current status. Neurobiology of depression 2011, CRC Press. F. Lopez Munoz, C. Alamo (Eds.).
7. Caberlotto L., Hurd Y.L. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. NeuroReport 1999, 10:1747-1750.
8. Jimenez-Vasquez P.A., Mathe A.A., Thomas J.D., Riley E.P., Ehlers C.L. Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Research Developmental Brain Research 2001, 131:149-152.
9. Zambello E., Fuchs E., Abumaria N., Rygula R., Domenici E., Caberlotto L. Chronic psychosocial stress alters NPY system: different effects in rat and tree shrew. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:122-130.
10. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989, 98:524-529.
11. Redrobe J.P., Dumont Y., Fournier A., Baker G.B., Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 2005, 26:1394-1400.
12. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. European Journal of Pharmacology 2000, 387:R9-R10.
13. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjogren M., et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. Journal of Psychiatric Research 2004, 38:113-121.
14. Hou C., Jia F., Liu Y., Li L. CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Research 2006, 1095:154-158.
15. Olsson A., Regnell G., Traskman-Bendz L., Ekman R., Westrin A. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. European Neuropsychopharmacology 2004, 14:479-485.
16. Sjoholm L.K., Melas P.A., Forsell Y., Lavebratt C. PreproNPY Pro7 protects against depression despite exposure to environmental risk factors. Journal of Affective Disorders 2009.
17. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001.
18. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacological Reviews 1998, 50:143-150.
19. Dumont Y., Morales-Medina J.C., Quirion R. Neuropeptide Y an its role in anxiety-related disorders. Transmitters and modulators in health and disease 2009, 51-82. Springer, Kato Bunmeisha. S. Shioda, I. Homma, N. Kato (Eds.).
20. 5 receptors in rodents, guinea pig, and primates brains. Journal of Comparative Neurology 1998, 402:372-384.
21. 5 receptor subtype. Neuroendocrinology 2001, 74:106-119.
22. 5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology 2011, 60:328-335.
23. 5 receptor increases food intake in rats. Journal of Biological Chemistry 2000, 275:36043-36048.
24. 5 stimulate different phases of feeding in guinea pigs. British Journal of Pharmacology 2003, 139:1433-1440.
25. 5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. Journal of Neurophysiology 2002, 87:558-566.
26. Sajdyk T.J., Schober D.A., Gehlert D.R. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 2002, 43:1165-1172.
27. 5 receptors in anxiety and sedation. Journal of Neuroscience Research 2004, 77:723-729.
28. Mitra R., Sapolsky R.M. Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5573-5578.
29. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacology & Therapeutics 1997, 74:299-316.
30. Morales-Medina J.C., Dumont Y., Benoit C.E., Bastianetto S., Flores G., Fournier A., et al. Role of neuropeptide Y Y(1) and Y(2) receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neuropharmacology 2012, 62:200-208.
31. Wang D., Noda Y., Tsunekawa H., Zhou Y., Miyazaki M., Senzaki K., et al. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behavioural Brain Research 2007, 178:262-273.
32. Stein-Behrens B., Mattson M.P., Chang I., Yeh M., Sapolsky R. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. Journal of Neuroscience 1994, 14:5373-5380.
33. Hasegawa S., Watanabe A., Nguyen K.Q., Debonnel G., Diksic M. Chronic administration of citalopram in olfactory bulbectomy rats restores brain 5-HT synthesis rates: an autoradiographic study. Psychopharmacology 2005, 179:781-790.
34. Tanaka S., Fan L.W., Tien L.T., Park Y., Liu-Chen L.Y., Rockhold R.W., et al. Butorphanol dependence increases hippocampal kappa-opioid receptor gene expression. Journal of Neuroscience Research 2005, 82:255-263.
35. Findeisen M., Rathmann D., Beck-Sickinger A.G. Structure-activity studies of RFamide peptides reveal subtype-selective activation of neuropeptide FF1 and FF2 receptors. ChemMedChem 2011, 6:1081-1093.
36. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
37. Redrobe J.P., Dumont Y., Herzog H., Quirion R. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behavioural Brain Research 2003, 141:251-255.
38. Mar A., Spreekmeester E., Rochford J. Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacology Biochemistry and Behavior 2002, 73:703-712.
39. Kalueff A.V., Tuohimaa P. Contrasting grooming phenotypes in C57Bl/6 and 129S1/SvImJ mice. Brain Research 2005, 1028:75-82.
40. Kalueff A.V., Tuohimaa P. Contrasting grooming phenotypes in three mouse strains markedly different in anxiety and activity (129S1, BALB/c and NMRI). Behavioural Brain Research 2005, 160:1-10.
41. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neuroscience & Biobehavioral Reviews 2005, 29:627-647.
42. Song C., Earley B., Leonard B.E. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain, Behavior, and Immunity 1996, 10:1-16.
43. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behavioural Pharmacology 1997, 8:523-532.
44. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
45. Gregus A., Wintink A.J., Davis A.C., Kalynchuk L.E. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behavioural Brain Research 2005, 156:105-114.
46. Kalynchuk L.E., Gregus A., Boudreau D., Perrot-Sinal T.S. Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behavioral Neuroscience 2004, 118:1365-1377.
47. 1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
48. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods 1980, 2:219-238.
49. File S.E., Seth P. A review of 25 years of the social interaction test. European Journal of Pharmacology 2003, 463:35-53.
50. 1 receptors. Brain Research 2009, 1266:45-53.
51. Vieyra-Reyes P., Mineur Y.S., Picciotto M.R., Tunez I., Vidaltamayo R., Drucker-Colin R. Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. Brain Research Bulletin 2008, 77:13-18.
52. 5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity. Neuropeptides 2012, 46:71-79.
53. Holmes P.V., Davis R.C., Masini C.V., Primeaux S.D. Effects of olfactory bulbectomy on neuropeptide gene expression in the rat olfactory/limbic system. Neuroscience 1998, 86:587-596.
54. Primeaux S.D., Holmes P.V. Olfactory bulbectomy increases met-enkephalin- and neuropeptide-Y-like immunoreactivity in rat limbic structures. Pharmacology Biochemistry and Behavior 2000, 67:331-337.
55. 5 receptor subtype in the rat brain. Journal of Neuroscience 1998, 18:5565-5574.
56. Karssen A.M., Her S., Li J.Z., Patel P.D., Meng F., Bunney W.E., et al. Stress-induced changes in primate prefrontal profiles of gene expression. Molecular Psychiatry 2007, 12:1089-1102.
57. 5 receptor variants. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008, 147B:510-516.
58. 5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydrobenzothiepino[5,4-d]thiazol-2-yl)amino]cycloh exyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity. Journal of Pharmacology and Experimental Therapeutics 2009, 328:900-911.
59. Kask A., Vasar E., Heidmets L.T., Allikmets L., Wikberg J.E. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. European Journal of Pharmacology 2001, 414:215-224.
60. 5 receptor blockade. International Journal of Obesity and Related Metabolic Disorders 2001, 25:84-94.
61. 5 receptor antagonist in diet-induced obese mice. Peptides 2009, 30:1318-1322.
62. Parker E.M., Balasubramaniam A., Guzzi M., Mullins D.E., Salisbury B.G., Sheriff S., et al. [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 2000, 21:393-399.
63. 5 receptor subclass. World Journal of Gastroenterology 2008, 14:6312-6317.
64. 5 neuropeptide Y receptor in feeding and obesity. Nature Medicine 1998, 4:718-721.
65. Kalueff A.V., Tuohimaa P. Contrasting grooming phenotypes in C57Bl/6 and 129S1/SvImJ mice. Brain research 2004, 1028:75-82.
66. Cryan J.F., Page M.E., Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 2005, 182:335-344.